a validated technology platform
Our virosome vaccine technology and know-how has been and continues to be validated through high value partnerships and collaboration with some of the world’s leading research funding organizations, pharma and biotech companies.
We have been able to attract continued grant funding for our promising HIV and malaria vaccines, while we have signed several license, collaboration and R&D project agreements with large Pharma and with biotech companies in the immune oncology and allergy space.
Early 2014, our RSV virosome vaccine and technology was selected by Astellas – ClearPath as the most promising RSV vaccine for the Astellas vaccine franchise targeting infectious diseases. Following a thorough due diligence of Mymetics’ virosome IP, know-how and the RSV virosome vaccine preclinical results and construct, we signed an exclusive license and collaboration agreement for our RSV virosome based vaccine funded by Astellas, a leading Japanese pharma company.
On January 29, 2016 Mymetics announced that the collaboration agreement will be discontinued, with effective date July 25, 2016.
Mymetics is currently evaluating new possible partnerships around the RSV virosome vaccine IP, know-how and deep expertise that has been built during this collaboration.
In close cooperation with the Texas Biomedical Research Institute, our HIV vaccine candidate obtained funding from the Bill & Melinda Gates Foundation to perform a study in non-human primates, replicating a smaller study in which the vaccine provided an unprecedented 100% protection in macaque monkeys. The Mymetics’ HIV vaccine is the first with a demonstrated ability to prevent viral transmission in primates.
On April 29, 2019, the National Institutes of Health ("NIH") awarded the Company and Texas Biomedical Research Institute ("Texas Biomed") later replaced with University of Louisiana at Lafayette, a five-year grant for the project. The project started on May 1, 2019 and is planned for five years. The overall budget related to the project is USD 8,850k. See for more information below under Grant Financing.
Our virosome technology has been selected by PATH-MVI, the world leading malaria vaccine research funding organization, to be evaluated for a transmission blocking malaria vaccine based on the antigens of LMIV (NIAID-HIV).
Since 2017, Mymetics has been improving the malaria vaccine candidate against blood and liver stage of the Pf parasite. This is a collaboration with the Swiss Tropical Institute, Oxford University and the European Union Transvac2 program.
Since April 2020, Mymetics is collaborating with leading academic institutions like Baylor College of Medicine in Texas, the Amsterdam Medical Center (AMC) in the Netherlands, and Bern University Hospital in Switzerland and has received funding and services from Swiss Innovation Agency (Innosuisse) and the European Union under the Horizon 2020 Transvac2 program.
More than 30 years of experience in the field of virosome vaccines, a unique R&D expertise, and intellectual property rights, makes Mymetics the global leader in this field. A focused strategy based on a sound scientific approach have resulted in the development of a rich pipeline of vaccine candidates...Read more
Few companies in the world have developed such a powerful technology platform and a unique know-how to develop next-generation vaccines for infectious diseases and immunotherapies for allergies and oncology...Read more